Cost of Subcutaneous Immunotherapy in a Large Insured Population in the United States.
CONCLUSIONS: This study showed 15% of patients may have costly inconsistent SCIT treatment. Greater understanding is needed regarding the reasons for inconsistent use of subcutaneous allergy immunotherapy.
PMID: 30091647 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Allergy | Allergy & Immunology | Hay Fever | Immunotherapy | Insurance | Medicare | Research | Study | USA Health